MedTrace Logo

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study

NCT02612116 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2016-10-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the differences in pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite depending on the strategy of the drug administration in patients with unstable angina pectoris.

Conditions

  • Unstable Angina Pectoris

Interventions

DRUG

Pulverized ticagrelor sublingually

Pulverized ticagrelor (180 mg) administered sublingually

DRUG

Pulverized ticagrelor orally

Pulverized ticagrelor (180 mg) administered orally

DRUG

Integral ticagrelor

Integral ticagrelor (180 mg) administered orally

Sponsors & Collaborators

  • Collegium Medicum w Bydgoszczy

    lead OTHER

Principal Investigators

  • Jacek Kubica, MD., PhD. · Cardiology Department, Dr. A. Jurasz University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-31
Completion
2016-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612116 on ClinicalTrials.gov